Clinical trials: Irritable Bowel Syndrome (IBS)
IBS - Irritable Bowel Syndrome
Effect of Postbiotic Product on Colonic Barriers in IBS
Impaired intestinal permeability and microbial dysbiosis are important pathophysiological mechanisms underlying irritable bowel syndrome (IBS).
- Trial name
- NCT05475314
- Testing
- ReFerm(R)
- Where
- Sweden
- Volunteers
- 30 people
- Sponsor
- Nordisk Rebalance A/S
Irritable Bowel Syndrome
Mesalazine Treatment in IBS (The MIBS Study)
Irritable bowel syndrome (IBS) is a condition characterised by abdominal pain or discomfort in combination with altered bowel function (stool frequency and/or stool consistency), currently defined by the Rome III criteria.
- Trial name
- MIBS (NCT01699438)
- Testing
- Mesalazine
- Where
- 3 sites in Sweden
- Volunteers
- 211 people
- Sponsor
- Hans Törnblom